Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.
Astellas Americas has a new VP in its Medical Affairs Oncology therapeutic area, and a new VP and an executive director of promotions in its corporate communications organization.
Jason D. Hanson was appointed president, CEO and director of enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs.
Thane Wettig was appointed to the newly created role of chief marketing officer and metabolic franchise head at Intarcia Therapeutics Inc.
Richard Klinghoffer, Ph.D., was named CEO of Presage Biosciences.
Genesis Drug Discovery & Development appointed Olesia Buiakova, M.D., Ph.D., as chief scientific officer.
As drug prices fall under increased scrutiny, payers and regulators are targeting some key initiatives that could change the dynamic of pharmacy benefit management over the next 12 months. These emerging trends point to potentially rougher terrain for drugmakers looking to increase market share as payers take a more active role in enforcing formularies.
Novartis launched its Galaxies of Hope app, a unique digital experience created to support the neuroendocrine tumor community.
The CME provider Rockpointe launched the first CME-certified course ever offered on Amazon Echo through the AudioEducate platform with joint providers Potomac Center for Medical Education (PCME) and the Academy of Physicians in Clinical Research (APCR).
Continuing its efforts to address high prescription drug costs, insurer Highmark entered into a new outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.
